| The placental gene PEG10 promotes progression of neuroendocrine prostate cancer S Akamatsu, AW Wyatt, D Lin, S Lysakowski, F Zhang, S Kim, C Tse, ... Cell reports 12 (6), 922-936, 2015 | 223 | 2015 |
| Optimally discriminative subnetwork markers predict response to chemotherapy P Dao, K Wang, C Collins, M Ester, A Lapuk, SC Sahinalp Bioinformatics 27 (13), i205-i213, 2011 | 118 | 2011 |
| Heterogeneity in the inter-tumor transcriptome of high risk prostate cancer AW Wyatt, F Mo, K Wang, B McConeghy, S Brahmbhatt, L Jong, ... Genome biology 15 (8), 1-14, 2014 | 92 | 2014 |
| GATA2 as a potential metastasis-driving gene in prostate cancer YT Chiang, K Wang, L Fazli, RZ Qi, ME Gleave, CC Collins, PW Gout, ... Oncotarget 5 (2), 451, 2014 | 66 | 2014 |
| Stromal gene expression is predictive for metastatic primary prostate cancer F Mo, D Lin, M Takhar, VR Ramnarine, X Dong, RH Bell, SV Volik, ... European urology 73 (4), 524-532, 2018 | 60 | 2018 |
| Identification of DEK as a potential therapeutic target for neuroendocrine prostate cancer D Lin, X Dong, K Wang, AW Wyatt, F Crea, H Xue, Y Wang, R Wu, RH Bell, ... Oncotarget 6 (3), 1806, 2015 | 54 | 2015 |
| HIT'nDRIVE: patient-specific multidriver gene prioritization for precision oncology R Shrestha, E Hodzic, T Sauerwald, P Dao, K Wang, J Yeung, ... Genome research 27 (9), 1573-1588, 2017 | 41 | 2017 |
| Enhanced anticancer activity of a combination of docetaxel and Aneustat (OMN54) in a patient-derived, advanced prostate cancer tissue xenograft model S Qu, K Wang, H Xue, Y Wang, R Wu, C Liu, AC Gao, PW Gout, ... Molecular oncology 8 (2), 311-322, 2014 | 33 | 2014 |
| HIT'nDRIVE: Multi-driver Gene Prioritization Based on Hitting Time. R Shrestha, E Hodzic, J Yeung, K Wang, T Sauerwald, P Dao, ... RECOMB, 293-306, 2014 | 13 | 2014 |
| A meta-analysis approach for characterizing pan-cancer mechanisms of drug sensitivity in cell lines K Wang, R Shrestha, AW Wyatt, A Reddy, J Lehár, Y Wang, A Lapuk, ... PLoS One 9 (7), e103050, 2014 | 11 | 2014 |
| Chromoplexy: a new paradigm in genome remodeling and evolution K Wang, Y Wang, CC Collins Asian journal of andrology 15 (6), 711, 2013 | 8 | 2013 |
| GATA2: Potential role as a prostate cancer metastasis-driving gene YT Chiang, K Wang, F Crea, C Collins, P Gout, Y Wang Cancer Research 74 (19_Supplement), 2001-2001, 2014 | 2 | 2014 |
| MP51-15 PREDICTIVE VALUE AND POTENTIALS FOR CO-TARGETED THERAPY OF STAT1 SIGNALING IN GEMCITABINE/CISPLATIN RESISTANT BLADDER CANCER T Hayashi, K Ikeda*, R Seiler, RH Bell, S Ettinger, K Wang, HZ Oo, H Abdi, ... The Journal of Urology 201 (Supplement 4), e729-e729, 2019 | | 2019 |
| Predictive value and potentials for co-targeted therapy of STAT1 signaling in gemcitabine/cisplatin resistant bladder cancer T Hayashi, K Ikeda, R Seiler, RH Bell, S Ettinger, K Wang, HZ Oo, H Abdi, ... European Urology Supplements 18 (1), e234, 2019 | | 2019 |
| 925 STAT1 inhibition restored chemotherapy sensitivity in cisplatin/gemcitabine resistant bladder cancer T Hayashi, R Seiler, R Bell, S Ettinger, K Wang, A Goriki, HZ Oo, S Awrey, ... European Urology Supplements 3 (15), e925, 2016 | | 2016 |
| MP49-09 ACTIVATION OF IFN/STAT1 SIGNALING IN CISPLATIN/GEMCITABINE RESISTANT BLADDER CANCER T Hayashi, R Seiler, RH Bell, S Ettinger, K Wang, S Awrey, K Gust, ... The Journal of Urology 193 (4S), e606-e606, 2015 | | 2015 |
| A systems biology approach for identifying markers of chemotherapy response K Wang University of British Columbia, 2012 | | 2012 |
The Phuong DaoMemorial Sloan Kettering Cancer CenterVerified email at mskcc.org
